You are here:
| Reference : Pharma-clinics. Le medicament du mois. Le formoterol (Oxis Turbohaler). |
| Scientific journals : Article | |||
| Human health sciences : Pharmacy, pharmacology & toxicology | |||
| http://hdl.handle.net/2268/12876 | |||
| Pharma-clinics. Le medicament du mois. Le formoterol (Oxis Turbohaler). | |
| French | |
| [fr] Drug clinics. Drug of the month. Formoterol (Oxis turbohaler) | |
Scheen, André  [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >] | |
| 1998 | |
| Revue Médicale de Liège | |
| Hopital de Baviere | |
| 53 | |
| 11 | |
| 715-8 | |
| 0370-629X | |
| Liège | |
| Belgique | |
| [en] Administration, Inhalation ; Adrenergic beta-Agonists/administration & dosage/therapeutic use ; Adult ; Airway Obstruction/drug therapy ; Asthma/drug therapy/prevention & control ; Bronchi/drug effects ; Bronchodilator Agents/administration & dosage/therapeutic use ; Child ; Ethanolamines/administration & dosage/therapeutic use ; Humans ; Nebulizers and Vaporizers ; Receptors, Adrenergic, beta-2/drug effects ; Time Factors | |
| [en] Formoterol, commercialized by Astra under the trade name Oxis, is a new potent and selective agonist of beta-2 adrenergic receptors, which is used with a specific device (Turbohaler) allowing effective inhalation. Bronchodilatation occurs rapidly, within 1-3 minutes after inhalation, and lasts about 12 hours after the administration of a unique dose. Oxis Turbohaler is indicated to reduce symptoms associated with bronchial obstruction in asthmatic patients when the control of asthma is not achieved with inhaled corticoid therapy. It is not indicated for the treatment of acute crisis. It is presented as powder vials for inhalation (4.5 or 9 micrograms per dose). The usual dose in adults is 1-2 inhalations 1-2 times per day, in the morning and/or in the evening (bedtime administration should be recommended in case of nocturnal asthma). There is not enough data for treating children. The lowest dose allowing adequate control of asthma should be selected for chronic treatment. | |
| http://hdl.handle.net/2268/12876 |
There is no file associated with this reference.
All documents in ORBi are protected by a user license.
